The influence of ketamine upon human plasma cholinesterase (E.C. 3.1.1.8) was determined by means of a colorimetric assay technique at 25 °C, pH 7.7 with butyrylthiocholine as substrate. Ketamine caused a reversible inhibition of cholinesterase (pI 50 = 2.75; apparent K { = 4.94 x 10~4 M). The kinetic analysis of the inhibitory action revealed a mixed competitive/non-competitive type of mechanism with a prevalence of the non-competitive component (a-value = 4.9). A decrease in cholinesterase activity is thought to be a result of a conformational change of the enzyme protein which is induced by a reversible binding of ketamine to anionic side receptors in the vicinity of the active centre.
The influence of ketamine upon human plasma cholinesterase (E.C. 3.1.1.8) was determined by means of a colorimetric assay technique at 25 °C, pH 7.7 with butyrylthiocholine as substrate. Ketamine caused a reversible inhibition of cholinesterase (pI 50 = 2.75; apparent K { = 4.94 x 10~4 M). The kinetic analysis of the inhibitory action revealed a mixed competitive/non-competitive type of mechanism with a prevalence of the non-competitive component (a-value = 4.9) . A decrease in cholinesterase activity is thought to be a result of a conformational change of the enzyme protein which is induced by a reversible binding of ketamine to anionic side receptors in the vicinity of the active centre.
Ketamine (2-(2-chlorophenyl)-2-methylaminocyclohexanone HC1; Ketalar, Ketanest) is an i.v. general anaesthetic agent producing a mental state which has been described as "dissociative anaesthesia" (Domino, Chodoff and Corssen, 1965) . This state is characterized by profound analgesia, unconsciousness with minimum depression of the protective reflexes, and normal to slightly enhanced skeletal muscle tone with cardiovascular and respiratory stimulation. In a recent survey of the current status of ketamine anaesthesia, Bovill and colleagues (1971) reported that ketamine prolongs the action of suxamethonium. These authors used the return of spontaneous respiration after the i.v. administration of suxamethonium as a measure of neuromuscular blockade. Johnston, Miller and Way (1974) , however, reported that there was no interaction of ketamine with suxamethonium. Neuromuscular blockade was measured by noting the force of thumb adduction after electrical stimulation of the ulnar nerve. The different findings were explained by the different methods employed to study the effect on neuromuscular transmission.
Assuming that there is a prolonged action of suxamethonium following the injection of ketamine, this side-effect of ketamine might be interpreted as being determined by an inhibition of plasma cholinesterase resulting in a decrease in the rate of the enzymatic hydrolysis of suxamethonium. Experimental evidence for ketamine's ability to inhibit this enzyme was first provided by Cohen and colleagues (1974) . These authors examined the effect of ketamine on bovine brain acetylcholinesterase (AChE, E.C. 3.1.1.7) and observed the changes in the concentration of acetylcholine in the brains of rats. The present in vitro investigation was undertaken to study the influence of this anaesthetic agent upon human plasma cholinesterase, and to examine possible interactions between ketamine and suxamethonium.
MATERIALS AND METHODS

Assay method
Human plasma cholinesterase (butyrylcholinesterase, BuChE) activity was determined by means of a colorimetric assay technique (Merckotest No. 3337) recently described in detail (Schuh, 1975) . In brief, butyrylthiocholine was used as the substrate (5.69 x 10~3 M), and the thiocholine produced by enzymatic hydrolysis reacted stoichiometrically with 5,5'-dithiobis-2-nitrobenzoate to form 5-mercapto-2-nitrobenzoate (yellow colour, molar extinction coefficient for a 1.0-cm light path: 13.3 x 10~6 cm 2 x mole" 1 ) which was estimated photometrically at Hg 405 nm (Eppendorf 1100M photometer and 4412 compensation recorder). The final volume in the cuvette was 2.11 ml.
Enzyme and inhibitor
Different samples of pooled human plasma were used as a source of enzyme (acylcholine acylhydrolase, E.C. 3.1.1.8) and stored at 4 °C during the course of this investigation. The plasma was obtained from the heparinized blood of healthy subjects, who were not receiving any medication, after centrifuging the blood at 1500 xg for 10 min. The rate of spontaneous non-enzymatic hydrolysis of butyrylthiocholine was determined before the addition of plasma and subtracted from the actual measurement of the BuChE activity expressed as (fxmole x ml" 1 x min" 1 ). Ketamine (molecular weight: 237.72) was prepared from a stock solution (50 mg/ml). Preliminary experiments were performed employing 0.9% sodium chloride; no significant change in BuChE activity was observed. Ketamine was equilibrated immediately with BuChE and the inhibition was reversible upon dilution. The ketamine concentrations given in this paper are related to the free base of ketamine (non-ionized form).
Enzyme kinetics
The experimental data were evaluated and interpreted according to Webb (1963) . The procedures are based upon the fundamental Michaelis-Menten equation (1913) which is applicable in our situation because BuChE obeys hyperbolic saturation kinetics:
where v = velocity of reaction at any substrate concentration; F max = maximum attainable velocity when the enzyme is saturated with substrate; 5 = substrate concentration; K M = Michaelis-Menten constant, numerically equal to the substrate concentration required for half-maximum velocity. The parameters of enzyme kinetics were obtained from different non-logarithmic linear transformations of the above equation.
RESULTS
Human plasma cholinesterase (100% activity: 5.46 ijimole x ml" 1 x min" 1 ) was inhibited by ketamine in a dose-dependent manner ( fig. 1 ), pI 50 (negative logarithm of the molar concentration of inhibitor required to produce 50% inhibition of the enzyme) being 2.75. pure competitive inhibitor, K max would be unchanged and-Kjj would increase, whereas in the presence of a pure non-competitive inhibitor, K M would be unchanged and K max would decrease. A mixed competitive/non-competitive type of inhibition is further indicated by the substrate-inhibitor interaction constant a (measure of the change in affinity induced by the inhibitor) which is approximately 4.9 (co > a > 1). which is located neither on the .y-axis nor on the xaxis:
The a-value provides an estimate of the proportion of the two types of antagonism for ketamine. The numerical value of a is infinite in the case of a pure competitive inhibition, and approaches 1 as the antagonism becomes purely non-competitive. In our case the a-value of ketamine is close to 1, indicating a preponderance of the non-competitive type of inhibition.
The apparent K { (dissociation constant for the enzyme-inhibitor complex) being about 4.94 x 10~4 M, was determined graphically by means of a Dixon plot (l/v v. I) ( fig. 5 ).
DISCUSSION
The present results prove that the i.v. anaesthetic agent ketamine is a reversible inhibitor of human plasma cholinesterase. However, the concentrations of ketamine required to inhibit this enzyme are slightly larger than those usually administered in clinical practice. The following rough calculation was performed. Assuming that ketamine 2 mg/kg body weight is injected i.v. in a 70-kg patient; the initial distribution within the plasma volume (approximately 4.5% of body weight) will result theoretically in a ketamine concentration of about 4.4 x 10~5 g/ml and the further distribution into the extracellular compartment (about 20% of body weight) leads to a ketamine concentration of about 10-5 g/ml. It has to be emphasized that these numerical values are very simplified estimates which do not, for example, take into account protein binding, and cellular uptake of ketamine. Thus, under clinical conditions an interference by ketamine with the enzymatic hydrolysis of suxamethonium appears to be negligible; it should not cause any clinical problems, especially if it is taken into account (Bovill et al., 1971) . As indicated by the substrate-inhibitor constant a, the ketamine inhibition of BuChE consists of a very small competitive component and a predominant non-competitive component. Under our experimental conditions (pH = 7.7) the ketamine molecule is partly ionized and contains a positively charged nitrogen atom (pK a = 7.4). According to the HendersonHasselbalch equation: pH = pK a +log (base/salt) the ratio of the concentration of free base to the concentration of the ionized molecule is determined by the difference between pH and pK a (Riggs, 1963) . It can be calculated by a slight rearrangement of the above equation: log (base/salt) = pH-pK a = 7.7-7 .4 = 0.3 (base/salt) = antilog 0.3 = 1.99
This means that at pH 7.7 about 33.4% of the drug is positively charged. To illustrate this, at I 50 the concentration of ketamine (base+salt) = 4.18 x 10~* g/ml. Simultaneous solution of the two equations: (base/salt) = 1.99, and (base+salt) = 4.18 x 10~4 g/ml, gives the concentration of the ionized form of ketamine: 1.40 x 10~4 g/ml. In patients under physiological conditions (pH 7.4) the percentage of ionized ketamine will be even larger (about 50%).
As regards the mechanism of ketamine inhibition, only a speculative conclusion from analogy can be provided. The active centre of both AChE and BuChE includes an anionic site and an esteratic site (Bergmann, 1955) with a greater importance and specificity of the anionic site in AChE than in BuChE (Augustinson, 1966) . The competitive component of the inhibition may reflect a direct interference of the positively charged moiety of ketamine with the anionic site of the active centre. This competitive interaction, however, must be very small and comparatively unimportant because of the prevailing non-competitive component; the latter indicates no substantial impairment of the substrate binding to the anionic site. Accordingly it seems to be more plausible that ketamine in addition is reversibly bound to other anionic side-receptors in the neighbourhood of the active centre. This non-specific binding could induce a conformational change in the enzyme protein. A similar mode of action has been suggested by Cohen and colleagues (1974) with respect to the ketamine inhibition of mammalian brain AChE and by Kitz, Brasswell and Ginsburg (1970) and Liillmann and colleagues (1971) for other AChE inhibiting agents (muscle relaxants and alkane-bis-onium compounds). This interpretation is based on the hypothesis that the function of the active centre of cholinesterase can be influenced by drugs bound to the adjacent regions (Koshland, 1960 (Koshland, , 1963 Belleau, 1965; Wilson, 1967) . The binding of the substrate to the classical anionic site is not impaired by this. However, the second step of the substrate-enzyme interaction, namely the acylation-desacylation of the esteratic site becomes more difficult, thus decreasing the cholinesterase activity.
INFLUENCE DE LA KETAMINE SUR LA CHOLINESTERASE DU PLASMA HUMAIN RESUME L'influence de la ketamine sur la cholinesterase du plasma humain (E.C. 3.1.1.8) a ete determinee a l'aide d'une technique de dosage colorimetrique a 25 °C pH 7,7, en utilisant la butyrylthiocholine comme substratum. La ketamine a provoque une inhibition reversible de la cholinesterase (pl 6o = 2,75; Ki apparent = 4,94 x 10~4M). L'analyse cinetique de l'action d'inhibition a revele un type de mecanisme competitif/non competitif avec predominance des composants non competitifs (a-valeur = 4,9). On pense que la baisse dans Pactivite de la cholinesterase decoule d'un changement de conformation de la proteine des enzymes, induit par la liasion reversible de la ketamine sur le cote anionique des recepteurs, dans le voisinage du centre actif. 
DER EINFLUSS VON
SUMARIO
La influencia de la quetamina en la colinesterasa de plasma humano (E.C. 3.1.1.8) se determino por medio de una tecnica de ensayo colorimetrico a 25 °C, pH 7,7 con butiriltiocolina como substrato. La quetamina produjo una inhibition reversible de la colinesterasa (pl 6o ) = 2,75; aparente K[ = 4,94 x 10~4 M). El analisis quinetico de la action inhibitoria revel6 un tipo de mecanismo competitivo/ no competitivo mezclado con una prevalencia del componente no-competitivo (a-valor = 4,9). Se cree que un descenso en la actividad colinesterasa es un resultado de un cambio conformacional de la proteina encimica que se induce por un ligazon reversible de quetamina a receptores laterales anionicos en las cercanias del centro activo.
